Department of Oncology, Guizhou Provincial People's Hospital, Medical School of Guizhou University, Guizhou Cancer Center, Guiyang, Guizhou, China.
Department of Oncology, The People's Hospital of Qijiang District, Chongqing, Chongqing, China.
BMJ Open. 2023 Jul 7;13(7):e072945. doi: 10.1136/bmjopen-2023-072945.
An updated epidemiological analysis of gastrointestinal stromal tumour (GIST), the change of cancer-specific survival (CSS) and patterns of initial treatment are of interest.
A retrospective study using data from the Surveillance, Epidemiology and End Results (SEER) database.
A total of 5625 patients with GIST diagnosed between 2010 and 2019 were identified.
Age-standardised incidence rate (ASIR) and annual prevalence rate were calculated. SEER combined stage, period CSS rate and initial treatment were summarised. All the data were calculated by SEER*Stat software.
From 2010 to 2019, the ASIR of GIST increased from 0.79 to 1.02 per 100 000 person-years, with an increase of 2.4% annually. The increase was across age and sex subgroups. The prevalence trend was similar with the ASIR trend in each subgroup. The stage distributions were similar between different age groups, but varied among different primary tumour sites. More importantly, a stage shift from regional stage to localized stage at diagnosis was found, which may result in the improvement of CSS over years. Overall, the 5-year CSS rate of GIST was approximately 81.3%. Even for metastatic GIST, the rate exceeded 50%. Surgery was the most common treatment regimen for GIST, followed by surgery and systemic treatment. Whereas approximately 7.0% patients were undertreated, which was more pronounced among patients with distant and unknown stages.
The findings of this study suggest an improving early detection of GIST and an improving ability of accurate staging. Though most patients are effectively treated and perform good survivals, approximate 7.0% patients may be undertreated.
对胃肠道间质瘤（GIST）的流行病学进行更新分析，了解癌症特异性生存率（CSS）的变化和初始治疗模式。
使用来自监测、流行病学和最终结果（SEER）数据库的数据进行回顾性研究。
共确定了 2010 年至 2019 年间诊断为 GIST 的 5625 例患者。
计算年龄标准化发病率（ASIR）和年患病率。总结 SEER 联合分期、时期 CSS 率和初始治疗情况。所有数据均由 SEER*Stat 软件计算。
从 2010 年到 2019 年，GIST 的 ASIR 从 0.79 增加到 1.02/10 万人口/年，每年增长 2.4%。这种增长在各年龄段和性别亚组中均存在。各亚组的患病率趋势与 ASIR 趋势相似。不同年龄组的分期分布相似，但不同原发肿瘤部位的分期分布不同。更重要的是，诊断时从区域性疾病向局限性疾病的分期转移，可能导致 CSS 多年来的改善。总体而言，GIST 的 5 年 CSS 率约为 81.3%。即使是转移性 GIST，其生存率也超过 50%。手术是 GIST 最常见的治疗方案，其次是手术联合系统治疗。然而，约有 7.0%的患者治疗不足，在远处和未知分期的患者中更为明显。
本研究结果表明，GIST 的早期检测得到改善，准确分期的能力得到提高。尽管大多数患者得到了有效治疗并取得了良好的生存结果，但仍有约 7.0%的患者可能治疗不足。
